Objective:The human parental brain is a discrete set of interacting brain circuits that related with child-care feelings and behaviors.The research on it can help us to understand the essence of human parent-child re-lationship formation.In order to provide materials for the research of human parental brain and related fields,the study is ready to establish a set of standardized Chinese Infant Affective Face Picture System.Methods:By using convenience sampling,a total of 360 infant facial expression pictures of 211 Chinese infants aged from 3 to 6 months were collected.After standard processing on the photos,196 unmarried and nulliparous college students re-cruited from two universities in Chongqing and Guiyang were asked to assess them.One hundred subjects assessed the emotion categories and intensity of the pictures,and other 96 subjects assessed the emotion valence,arousal and dominance of the selected pictures.Results:The Chinese Infant Affective Face Picture System,containing 117 hap-py,92 neutral,108 sad expression pictures,was established.At the same time,the corresponding average identifica-tion rate were 89%,77%,92%,the intensity were 5.83,5.15,and 6.19,the valence were 5.92,4.55 and 2.70,the arousal were 5.11,4.18,3.77,and the dominance were 5.02,4.93,and 4.91.The system could effectively stimu-late participants'emotional reactions.There were statistically significant differences in scores of the established va-lence,arousal and dominance index between the 3 kinds of expression pictures (Ps <0.01).Conclusion:The Chi-nese Infant Affective Face Picture System has higher reliability and validity.The system could be used as emotional stimulus materials for the study of parental brain or emotion researches.

Objective: To evaluate the real-world safety and curative effect of ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in non-cirrhotic or compensated cirrhotic patients. Methods: A real-world research method was adopted, and the research was conducted at three medical centers of mainland China. Non- cirrhotic or compensated cirrhotic patients with HCV genotype 1b infection who were initially treated with IFN/PEG-IFN-alpha combined with ribavirin, and ombitasvir combined with dasabuvir for 8 or 12 weeks were taken. Sustained virological response (SVR) and the incidence of adverse events during treatment and follow-up were evaluated after 12 weeks of drug withdrawal at OBV/PTV/r 25/150/100mg once daily and DSV 250mg, twice daily. Median and range were used for description of non-normally distributed data. Results: 80 cases of GT1b were included in this study. Of these 88.8% (71/80) were newly diagnosed, 12.5% (10/80) were compensated cirrhotic, 97.5% (78/80) received 12 weeks treatment, and 2.5% (2/80) received 8 weeks treatment. The rate of HCV RNA negative at EOT (end of treatment) was 100% (64/64). A total of 67 patients completed the treatment within 12 weeks, and 43 patients returned to the hospital for further consultations, and SVR12 was 100%(43/43). No patient discontinued the drugs because of an adverse event during treatment. Conclusion In the real world, Ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in China has 100% rates of EOT and SVR12 with well- tolerability and safety.